Notice2025-09651
Carlton Reico Mallard Jr.: Final Debarment Order
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 29, 2025
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Carlton Reico Mallard Jr. for a period of 10 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Mallard was convicted of one felony count under Federal law for introduction into interstate commerce a misbranded drug, with the intent to defraud and mislead, and one felony count of illegal importation of merchandise. The factual bases supporting Mr. Mallard's convictions, as described below, are for conduct relating to the importation into the United States of a drug or controlled substance. Mr. Mallard was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of February 23, 2025 (30 days after receipt of the notice), Mr. Mallard had not responded. Mr. Mallard's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 102 (Thursday, May 29, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 102 (Thursday, May 29, 2025)]
[Notices]
[Pages 22736-22737]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-09651]
[[Page 22736]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2024-N-5308]
Carlton Reico Mallard Jr.: Final Debarment Order
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is issuing an order
under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring
Carlton Reico Mallard Jr. for a period of 10 years from importing or
offering for import any drug into the United States. FDA bases this
order on a finding that Mr. Mallard was convicted of one felony count
under Federal law for introduction into interstate commerce a
misbranded drug, with the intent to defraud and mislead, and one felony
count of illegal importation of merchandise. The factual bases
supporting Mr. Mallard's convictions, as described below, are for
conduct relating to the importation into the United States of a drug or
controlled substance. Mr. Mallard was given notice of the proposed
debarment and was given an opportunity to request a hearing to show why
he should not be debarred. As of February 23, 2025 (30 days after
receipt of the notice), Mr. Mallard had not responded. Mr. Mallard's
failure to respond and request a hearing constitutes a waiver of his
right to a hearing concerning this matter.
DATES: This order is applicable May 29, 2025.
ADDRESSES: Any application by Mr. Mallard for termination of debarment
under section 306(d)(1) of the FD&C Act (21 U.S.C. 335a(d)(1)) may be
submitted at any time as follows:
Electronic Submissions
<bullet> Federal eRulemaking Portal: <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Follow the instructions for submitting comments. An application
submitted electronically, including attachments, to <a href="https://www.regulations.gov">https://www.regulations.gov</a> will be posted to the docket unchanged. Because
your application will be made public, you are solely responsible for
ensuring that your application does not include any confidential
information that you or a third party may not wish to be posted, such
as medical information, your or anyone else's Social Security number,
or confidential business information, such as a manufacturing process.
Please note that if you include your name, contact information, or
other information that identifies you in the body of your application,
that information will be posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
<bullet> If you want to submit an application with confidential
information that you do not wish to be made available to the public,
submit the application as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
<bullet> Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
<bullet> For a written/paper application submitted to the Dockets
Management Staff, FDA will post your application, as well as any
attachments, except for information submitted, marked, and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All applications must include the Docket No. FDA-
2024-N-5308. Received applications will be placed in the docket and,
except for those submitted as ``Confidential Submissions,'' publicly
viewable at <a href="https://www.regulations.gov">https://www.regulations.gov</a> or at the Dockets Management
Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.
<bullet> Confidential Submissions--To submit an application with
confidential information that you do not wish to be made publicly
available, submit your application only as a written/paper submission.
You should submit two copies total. One copy will include the
information you claim to be confidential with a heading or cover note
that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The
Agency will review this copy, including the claimed confidential
information, in its consideration of your application. The second copy,
which will have the claimed confidential information redacted/blacked
out, will be available for public viewing and posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>. Submit both copies to the Dockets Management
Staff. Any information marked as ``confidential'' will not be disclosed
except in accordance with 21 CFR 10.20 and other applicable disclosure
law. For more information about FDA's posting of comments to public
dockets, see 80 FR 56469, September 18, 2015, or access the information
at: <a href="https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf">https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf</a>.
Docket: For access to the docket, go to <a href="https://www.regulations.gov">https://www.regulations.gov</a>
and insert the docket number, found in brackets in the heading of this
document, into the ``Search'' box and follow the prompts and/or go to
the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852 between 9 a.m. and 4 p.m., Monday through Friday, 240-402-
7500. Publicly available submissions may be seen in the docket.
FOR FURTHER INFORMATION CONTACT: Jaime Espinosa, Division of Field
Enforcement, Office of Field Regulatory Operations, Office of
Inspections and Investigations, Food and Drug Administration, 240-402-
8743, or <a href="/cdn-cgi/l/email-protection#dfbbbabdbeadb2bab1abac9fb9bbbef1b7b7acf1b8b0a9"><span class="__cf_email__" data-cfemail="f99d9c9b988b949c978d8ab99f9d98d791918ad79e968f">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(b)(1)(D) of the FD&C Act (21 U.S.C. 335a(b)(1)(D))
permits debarment of an individual from importing or offering for
import any drug into the United States if FDA finds, as required by
section 306(b)(3)(C) of the FD&C Act, that the individual has been
convicted of a felony for conduct relating to the importation into the
United States of any drug or controlled substance.
On July 23, 2024, Mr. Mallard was convicted as defined in section
306(l)(1) of the FD&C Act in the United States District Court for the
Middle District of Florida when the court accepted his plea of guilty
and entered judgment against him for the offenses of Introduction into
Interstate Commerce of Misbranded Drugs with Intent to Defraud and
Mislead in violation of 21 U.S.C. 331(a) and 333(a)(2) (sections 301(a)
and 303(a)(2) of the FD&C Act) and of Illegal Importation of
Merchandise in violation of 18 U.S.C. 545. The underlying facts
supporting the conviction are as follows: As contained in the
Information, and in the Plea Agreement from his case, Mr. Mallard was
the president and director of Inspiring Estates, Inc., and an owner of
Golden Royal Honey USA (GRH). Mr. Mallard also operated the website
<a href="http://www.goldenroyalhoneyusa.com">www.goldenroyalhoneyusa.com</a> on behalf of GRH to market and offer for
sale misbranded drugs, specifically male enhancement products. Mr.
Mallard was a client of Fulfillment Company 1 (FC-1), a marketing and
online order fulfillment service, and used FC-1 to receive shipments of
these misbranded drug products unlawfully imported into the United
States from foreign nations. Between May 2020 and February 2021,
several packages addressed to GRH were seized by the United States
Customs and Border Protection (CBP). Mr. Mallard also received notices
from the FDA and/or CBP about the violative nature of the
[[Page 22737]]
products he was importing from China and other foreign countries.
On or about August 5, 2020, a Special Agent from the FDA's Office
of Criminal Investigations (OCI), while undercover, purchased items
through the GRH website. The three products were called ``Leopard
Miracle Honey,'' ``Vitamax Double Shot Honey,'' and ``Golden Royal
Honey VIP.'' After receiving the products, OCI sent them for laboratory
analyses at the FDA Forensic Chemistry Center (FCC). The FCC testing
and analyses confirmed that sildenafil was present in the ``Leopard
Miracle Honey'' while tadalafil was present in both the ``Vitamax
Double Shot Honey'' and ``Golden Royal Honey VIP.''
On or about February 27, 2021, Mr. Mallard was interviewed by CBP
officers. He confirmed that he operated an online business that
distributed honey products. CBP officers discovered Mr. Mallard
received text messages from DHL about incoming foreign parcels between
February 24, 2021, and February 26, 2021. On or about April 16, 2021, a
search and seizure warrant for GRH inventory was executed at FC-1.
During the execution of the warrant agents discovered hundreds of
products violative of the FDCA that were imported into the United
States from foreign countries. Thirty-eight (38) items were submitted
to the FCC for testing. Approximately thirty (30) tested positive for
sildenafil and/or tadalafil, all of which were violative of the FD&C
Act. Fulfillment and shipping records provided by FC-1 revealed that in
2020, FC-1 received 13,000 shipments on behalf of GRH and it processed
and shipped out over 12,000 orders. During 2020, Mr. Mallard received
approximately $764,749.64 for the sale of misbranded drugs that lacked
the required FDA approval.
FDA sent Mr. Mallard, by certified mail, on January 2, 2025, a
notice proposing to debar him for a 10-year period from importing or
offering for import any drug into the United States. The proposal was
based on a finding under section 306(b)(3)(C) of the FD&C Act that Mr.
Mallard's felony convictions under Federal law for Introduction into
Interstate Commerce of Misbranded Drugs with Intent to Defraud and
Mislead in violation of 21 U.S.C. 331(a) and 333(a)(2) (sections 301(a)
and 303(a)(2) of the FD&C Act) and of Illegal Importation of
Merchandise in violation of 18 U.S.C. 545, were for conduct relating to
the importation of any drug or controlled substance into the United
States because Mr. Mallard illegally imported and introduced misbranded
drug products into interstate commerce. In proposing a debarment
period, FDA weighed the considerations set forth in section 306(c)(3)
of the FD&C Act that it considered applicable to Mr. Mallard's offense
and concluded that the offense warranted the imposition of a 10-year
period of debarment.
The proposal informed Mr. Mallard of the proposed debarment and
offered him an opportunity to request a hearing, providing him 30 days
from the date of receipt of the letter in which to file the request,
and advised him that failure to request a hearing constituted a waiver
of the opportunity for a hearing and of any contentions concerning this
action. Mr. Mallard received the proposal and notice of opportunity for
a hearing on January 24, 2025. Mr. Mallard failed to request a hearing
within the timeframe prescribed by regulation and has, therefore,
waived his opportunity for a hearing and waived any contentions
concerning his debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Division of Field Enforcement Director, Office of
Inspections and Investigations, under section 306(b)(3)(C) of the FD&C
Act, under authority delegated to the Director, Division of
Enforcement, finds that Mr. Carlton Reico Mallard Jr. has been
convicted of multiple felonies under Federal law for conduct relating
to the importation into the United States of any drug or controlled
substance. FDA finds that the offenses should be accorded a debarment
period of 10 years, with the maximum possible period of debarment as
provided by section 306(c)(2)(A)(iii) of the FD&C Act for each felony
count to run consecutively.
As a result of the foregoing finding, Mr. Mallard is debarred for a
period of 10 years from importing or offering for import any drug into
the United States, effective (see DATES). Pursuant to section 301(cc)
of the FD&C Act (21 U.S.C. 331(cc)), the importing or offering for
import into the United States of any drug by, with the assistance of,
or at the direction of Mr. Mallard is a prohibited act.
Dated: May 22, 2025.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2025-09651 Filed 5-28-25; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 29, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.